LT3335B - Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which results from vascular lesions - Google Patents

Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which results from vascular lesions Download PDF

Info

Publication number
LT3335B
LT3335B LTIP580A LTIP580A LT3335B LT 3335 B LT3335 B LT 3335B LT IP580 A LTIP580 A LT IP580A LT IP580 A LTIP580 A LT IP580A LT 3335 B LT3335 B LT 3335B
Authority
LT
Lithuania
Prior art keywords
cholesterol
mpfg
phosphate
pyridoxal
ldl
Prior art date
Application number
LTIP580A
Other languages
English (en)
Lithuanian (lt)
Inventor
Werner Schneider
Britta Meyer
Erich F Elstner
Original Assignee
Steigerwald Arzneimittelwerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steigerwald Arzneimittelwerk filed Critical Steigerwald Arzneimittelwerk
Publication of LTIP580A publication Critical patent/LTIP580A/xx
Publication of LT3335B publication Critical patent/LT3335B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTIP580A 1990-05-25 1993-05-31 Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which results from vascular lesions LT3335B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4016963A DE4016963A1 (de) 1990-05-25 1990-05-25 Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben

Publications (2)

Publication Number Publication Date
LTIP580A LTIP580A (en) 1994-12-27
LT3335B true LT3335B (en) 1995-07-25

Family

ID=6407228

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP580A LT3335B (en) 1990-05-25 1993-05-31 Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which results from vascular lesions

Country Status (28)

Country Link
US (1) US5372999A (fr)
EP (1) EP0458287B1 (fr)
JP (1) JPH07119174B2 (fr)
KR (1) KR970005180B1 (fr)
CN (1) CN1050750C (fr)
AT (1) ATE142884T1 (fr)
AU (1) AU651108B2 (fr)
CA (1) CA2043228C (fr)
CZ (1) CZ280683B6 (fr)
DE (2) DE4016963A1 (fr)
DK (1) DK0458287T3 (fr)
EG (1) EG19730A (fr)
ES (1) ES2091262T3 (fr)
GR (1) GR3021077T3 (fr)
HR (1) HRP931445B1 (fr)
HU (1) HU219223B (fr)
IE (1) IE76728B1 (fr)
IL (1) IL98156A (fr)
IN (1) IN173057B (fr)
LT (1) LT3335B (fr)
LV (1) LV10046B (fr)
MD (1) MD306C2 (fr)
MX (1) MX171883B (fr)
RU (1) RU2041713C1 (fr)
SI (1) SI9110925A (fr)
SK (1) SK278896B6 (fr)
UA (1) UA26973A1 (fr)
ZA (1) ZA913692B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527820A1 (de) * 1995-07-28 1997-01-30 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
ATE306489T1 (de) 1999-03-08 2005-10-15 Medicure Inc Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
AU5840200A (en) * 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (fr) 1999-08-24 2001-03-01 Medicure International Inc. Traitement des pathologies cardio-vasculaires et connexes
DE60110054T2 (de) 2000-02-29 2006-03-09 Medicure International Inc. Cardioprotektive phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
NZ523815A (en) 2000-07-07 2004-07-30 Medicure Int Inc Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006050598A1 (fr) 2004-10-28 2006-05-18 Medicure International Inc. Analogues de pyridoxine à double activité anti-plaquettes et anti-coagulantes
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
JP2010535013A (ja) 2007-03-14 2010-11-18 シエラ モレキュラー コーポレイション 細胞および／または高分子の保存および／または安定化のための組成物、システムおよび方法
RU2484843C1 (ru) * 2012-04-03 2013-06-20 Алексей Кириллович Пехтерев Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2461742C2 (de) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (fr)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. W. MOREL, G. M. CHISOLM: "Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity", JOURNAL OF LIPID RESEARCH, 1989, pages 1827 - 1834
JOHN M.C. GUTTERIDGE, BARRY HALLIWELL: "The measurement and mechanism of lipid peroxidation in biological systems", TRENDS IN BIOCHEMICAL SCIENCES, 1990, pages 129 - 135
MASAFUMI KUZUYA ET AL.: "Protective role of intracellular glutathione against oxidized low density lipoprotein in cultured endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, pages 1466 - 1472
U. P. STEINBRECHER ET AL.: "Recognition of Oxidized Low Density Lipoprotein by the Scavenger Receptor of Macrophages Results from Derivatization of Apolipoprotein B by Products of Fatty Acid Peroxidation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 1989, pages 15216 - 15223

Also Published As

Publication number Publication date
SI9110925A (sl) 1998-06-30
DE4016963A1 (de) 1991-11-28
CA2043228C (fr) 1998-07-14
US5372999A (en) 1994-12-13
EG19730A (en) 1996-01-31
IL98156A0 (en) 1992-06-21
HRP931445B1 (en) 2000-04-30
ES2091262T3 (es) 1996-11-01
JPH04235130A (ja) 1992-08-24
LTIP580A (en) 1994-12-27
DE4016963C2 (fr) 1992-04-30
HUT58204A (en) 1992-02-28
HRP931445A2 (en) 1996-02-29
IE911783A1 (en) 1991-12-04
EP0458287B1 (fr) 1996-09-18
JPH07119174B2 (ja) 1995-12-20
DK0458287T3 (da) 1996-10-07
CZ280683B6 (cs) 1996-04-17
ATE142884T1 (de) 1996-10-15
AU651108B2 (en) 1994-07-14
SK278896B6 (sk) 1998-04-08
IN173057B (fr) 1994-02-05
LV10046A (lv) 1994-05-10
MX171883B (es) 1993-11-22
UA26973A1 (uk) 2000-02-28
MD306B1 (ro) 1995-10-31
HU219223B (en) 2001-03-28
AU7730191A (en) 1991-11-28
KR970005180B1 (ko) 1997-04-14
LV10046B (en) 1995-02-20
EP0458287A3 (en) 1992-04-08
HU911756D0 (en) 1991-12-30
GR3021077T3 (en) 1996-12-31
MD306C2 (ro) 1996-02-29
RU2041713C1 (ru) 1995-08-20
DE69122170T2 (de) 1997-02-20
EP0458287A2 (fr) 1991-11-27
IL98156A (en) 1996-06-18
CA2043228A1 (fr) 1991-11-26
CS156391A3 (en) 1992-02-19
ZA913692B (en) 1992-02-26
DE69122170D1 (de) 1996-10-24
IE76728B1 (en) 1997-11-05
KR910019616A (ko) 1991-12-19
CN1057391A (zh) 1992-01-01
CN1050750C (zh) 2000-03-29

Similar Documents

Publication Publication Date Title
LT3335B (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which results from vascular lesions
TZAGOURNIS et al. Interrelationships of hyperinsulinism and hypertriglyceridemia in young patients with coronary heart disease
Gacs et al. Significance of Ca-soap formation for calcium absorption in the rat.
Steinberg Role of oxidized LDL and antioxidants in atherosclerosis
US5763496A (en) Prevention of atherosclerosis using NADPH oxidase inhibitors
Chen et al. Effects of guar gum and wheat bran on lipid metabolism of rats
Illingworth et al. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Wheatley et al. Methylmercury poisoning in Canadian Indians—the elusive diagnosis
Yoshino et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)
WO1995000158A1 (fr) Complement dietetique comprenant du beta-sitosterol et de la pectine
ANNEGERS FUNCTION OF PANCREATIC JUICE AND OF BILE IN ASSIMILATION OF DIETARY TRIGLYCERIDE: A Review
World Health Organization Carbon disulfide
Christensson et al. Cholelithiasis in subjects with hypercalcaemia and primary hyperparathyroidism detected in a health screening.
Borhani Prevention of coronary heart disease in practice: implications of the results of recent clinical trials
MILLER et al. On the mechanism of action of nicotinic acid in lowering serum lipids
Sahlin et al. Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment
Fleischmajer Familial hyperlipoproteinemia type III
Moyer A current appraisal of drug therapy of atherosclerosis
NATIONALINSTITUTESOFH Detection
BERGEN JR et al. Approaches to the treatment of hypercholesteremia
Schettler Prevention and treatment of “atheromatous complications” of hypertension
Berkowitz et al. Management of the Hyperlipidemic Patient
Mack et al. Factors influencing the formation of new human coronary lesions: age, blood pressure, and blood cholesterol.
Jakimowicz Per-en postoperatieve choledochoscopie
Spjuth et al. Can the birth of a large infant predict risk for atherosclerotic vascular disease in the mother?

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20000531